Cad. Sci. USA 2010, 107, 186708675. 175. Hamdane, M.; Dourlen, P.; Bretteville, A.; Sambo, A.V.; Ferreira, S.; Ando, K.; Kerdraon, O.; B ard, S.; Geay, L.; Lippens, G.; et al. Pin1 enables for differential Tau dephosphorylation in neuronal cells. Mol. Cell. Neurosci. 2006, 1, 15560. 176. Lim, J.; Balastik, M.; Lee, T.H.; Nakamura, K.; Liou, Y.C.; Sun, A.; Finn, G.; Pastorino, L.; Lee, V.M.; Lu, K.P. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Investig. 2008, 118, 1877889. 177. Bulbarelli, A.; Lonati, E.; Cazzaniga, E.; Gregori, M.; Masserini, M. Pin1 affects Tau phosphorylation in response to A-oligomers. Mol. Cell. Neurosci. 2009, 42, 750. 178. Ma, S.L.; Pastorino, L.; Zhou, X.Z.; Lu, K.P. Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3 (GSK3) activity: Novel mechanism for Pin1 to guard against Alzheimer illness. J. Biol. Chem. 2012, 287, 6969973. 179. Tamayev, R.; Zhou, D.; D’Adamio, L. The interactome from the amyloid- precursor protein members of the family is shaped by phosphorylation of their intracellular domains. Mol. Neurodegener. 2009, four, 28. 180. Williamson, R.; Usardi, A.; Hanger, D.P.; Anderton, B.H. Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FEBS J. 2008, 22, 1552559. 181. Roberson, E.D.; Halabisky, B.; Yoo, J.W.; Yao, J.; Chin, J.; Yan, F.; Wu, T.; Hamto, P.; Devidze, N.; Yu, G.Q.; et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s illness. J. Neurosci. 2011, 31, 70011. 182. Hernandez, P.; Lee, G.; Sjoberg, M.; Maccioni, R.B. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (255): Involvement of lipid rafts.Eicosapentaenoic Acid J. Alzheimers. Dis. 2009, 16, 14956. 183. Scales, T.M.; Derkinderen, P.; Leung, K.Y.; Byers, H.L.; Ward, M.A.; Value, C.; Bird, I.N.; Perera, T.; Kellie, S.; Williamson, R.; et al. Tyrosine phosphorylation of tau by the SRC household kinases lck and fyn. Mol. Neurodegener. 2011, 6, 12. 184. Bhaskar, K.; Hobbs, G.A.; Yen, S.H.; Lee, G. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol. 2010, 36, 46277.Int. J. Mol. Sci. 2014,185. Usardi, A.Trastuzumab ; Pooler, A.PMID:24507727 M.; Seereeram, A.; Reynolds, C.H.; Derkinderen, P.; Anderton, B.; Hanger, D.P.; Noble, W.; Williamson, R. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J. 2011, 278, 2927937. 186. Pritchard, S.M.; Dolan, P.J.; Vitkus, A.; Johnson, G.W.V. The toxicity of tau in Alzheimer illness: Turnover, targets and potential therapeutics. J. Cell. Mol. Med. 2011, 15, 1621635. 187. Dou, F.; Netzer, W.J.; Tanemura, K.; Li, F.; Hartl, F.U.; Takashima, A.; Gouras, G.K.; Greengard, P.; Xu, H. Chaperones raise association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 2003, one hundred, 72126. 188. Miyata, Y.; Koren, J., III; Kiray, J.; Dickey, C.A.; Gestwicki, J.E. Molecular chaperones and regulation of tau good quality control:approaches for drug discovery in tauopathies. Futur. Med. Chem. 2011, three, 1523537. 189. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; de Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004, 13, 703.
